X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Elder Pharma Fact Sheet, Elder Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Elder Pharma Fact Sheet   (ELDER)

Here is the latest financial fact sheet of Elder Pharma. For more details, see the Elder Pharma quarterly results and Elder Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

ELDER PHARMA Price History

Price Rs 38.0
Mkt Cap Rs m 781
Vol '000 20.5
P/E X -0.2
P/CF X 2.6
EPS (TTM) Rs -220.6
% ch % 5.0
No. of shares m 20.54
% ch week % 5.0
% ch 1-mth % 27.1
% ch 12-mth % -64.5
52 week H/L Rs 118.8/20.4
(As on Sep 12, 2016 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

ELDER PHARMA Financials

No. of Mths
Year Ending
12
Mar-11
*
12
Mar-12
*
12
Mar-13
*
15
Jun-13
*
12
Jun-14
*
5-Yr Chart
Click to enlarge
ELDER PHARMA EQUITY SHARE DATA
High Rs440435416416380 
Low Rs321298202202188 
Sales per share (Unadj.) Rs470.0649.8799.3799.3491.2 
Earnings per share (Unadj.) Rs31.335.240.140.1-3.2 
Diluted earnings per shareRs31.335.240.140.1-3.2 
Cash flow per share (Unadj.) Rs45.351.761.661.614.4 
Dividends per share (Unadj.) Rs3.003.00000 
Adj. dividends per shareRs3.003.000.000.000.00 
Dividend yield (eoy) %0.80.8000 
Book value per share (Unadj.) Rs307.0341.1374.5374.5376.5 
Adj. book value per shareRs307.0341.1374.5374.5376.5 
Shares outstanding (eoy) m20.5420.5420.5420.5420.54 
Bonus/Rights/Conversions  PP---- 
Price / Sales ratio x0.80.60.40.40.6 
Avg P/E ratio x12.210.47.77.7-89.3 
P/CF ratio (eoy) x8.47.15.05.019.7 
Price / Book Value ratio x1.21.10.80.80.8 
Dividend payout %9.68.5000 
Avg Mkt Cap Rs m7,8157,5286,3486,3485,833 
No. of employees `0003.63.5NANANA 
Total wages/salary Rs m1,2261,7992,3312,3312,179 
Avg. sales/employee Rs Th2,674.63,773.8NMNMNM 
Avg. wages/employee Rs Th339.7508.6NMNMNM 
Avg. net profit/employee Rs Th178.0204.3NMNMNM 
ELDER PHARMA INCOME DATA
Net Sales Rs m9,65313,34816,41716,41710,089 
Other income Rs m87265327327257 
Total revenues Rs m9,73913,61316,74416,74410,346 
Gross profit Rs m1,3311,9902,7342,734-792 
Depreciation Rs m287340441441361 
Interest Rs m2811,0161,5481,5482,756 
Profit before tax Rs m8499001,0711,071-3,653 
Minority Interest Rs m70000 
Prior Period Items Rs m80000 
Extraordinary Inc (Exp) Rs m-4515-28-283,713 
Tax Rs m177193219219125 
Profit after tax Rs m642723824824-65 
Gross profit margin %13.814.916.716.7-7.8 
Effective tax rate %20.821.420.520.5-3.4 
Net profit margin %6.75.45.05.0-0.6 
ELDER PHARMA BALANCE SHEET DATA
Current assets Rs m8,2788,7828,7918,7919,240 
Current liabilities Rs m5,8036,9579,9989,9989,998 
Net working cap to sales %25.613.7-7.4-7.4-7.5 
Current ratio x1.41.30.90.90.9 
Inventory Days Days9180545446 
Debtors Days Days10793898960 
Net fixed assets Rs m7,4258,9739,6319,63110,124 
Share capital Rs m206206206206206 
"Free" reserves Rs m5,4365,7906,1216,1215,582 
Net worth Rs m6,3077,0067,6937,6937,734 
Long term debt Rs m5,0955,8257,0397,0394,889 
Total assets Rs m17,41519,99824,92524,92522,882 
Interest coverage x4.01.91.71.7-0.3 
Debt to equity ratio x0.80.80.90.90.6 
Sales to assets ratio x0.60.70.70.70.4 
Return on assets %5.38.79.59.511.8 
Return on equity %10.210.310.710.7-0.8 
Return on capital %9.615.017.617.622.3 
Exports to sales %2.42.11.91.93.0 
Imports to sales %3.62.31.81.80.4 
Exports (fob) Rs m228280318318307 
Imports (cif) Rs m35130629129143 
Fx inflow Rs m228280318318307 
Fx outflow Rs m388334361361125 
Net fx Rs m-160-54-43-43181 
ELDER PHARMA CASH FLOW
From Operations Rs m 657 148 194 166 11,754 
From Investments Rs m -1,507 -1,711 -632 -632 -561 
From Financial Activity Rs m 2,734 433 -67 -39 -6,762 
Net Cashflow Rs m 1,885 -1,131 -506 -506 4,432 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 39.6%
Foreign collaborators 0.0%
Indian inst/Mut Fund 7.5%
FIIs 16.8%
ADR/GDR 0.0%
Free float 36.1%
Shareholders 16,479
Pledged promoter(s) holding 77.6%
 

Company Information

REGD OFF Elder House, Plot No. C-9, Dalia Indl. Estate, Off Veera Desai Road, Mumbai-53
E-MAIL s.p.date@elderindia.com WEB www.elderindia.com
TELEPHONE (022) 2673 0058 FAX (022) 2673 0051
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Intime Spectrum, C-13, Pannalal Silk Mills Compd., LBS Marg, Mumbai - 78
AUDITOR S. S. Khandelwal & Co.
CHM: J. Saxena COMP SEC: S. P. Date YEAR OF INC: 1900 BSE CODE: 532322 FV (Rs): 10 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   AMAR REMEDIES  ALEMBIC LTD  SUN PHARMA  ASTRAZENECA PHARMA  UNICHEM LAB  

Compare ELDER PHARMA With:   AMAR REMEDIES  ALEMBIC LTD  SUN PHARMA  ASTRAZENECA PHARMA  UNICHEM LAB  

Compare ELDER PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week; Realty & Metal Stocks Plunge(Closing)

Indian share markets continued to languish in red in the afternoon session as rupee hit its weakest point since early April amid concerns.

Views on news

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ELDER PHARMA

ELDER PHARMA - ADCOCK INGRAM COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS